Andres Poveda, MD Initia Oncology Hospital Quironsalud Valencia, Spain 5 Live #ASCO20

4:57

Key Insights on Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

Ovarian Cancer

Ovarian Cancer Similar Videos

Similar Videos

"Andres Poveda, MD Initia Oncology Hospital Quironsalud Valencia, Spain 5 Live #ASCO20"

4:57

Key Insights on Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis.

ABOUT

Bio Ascend is an independent medical education company committed to supporting healthcare providers in their efforts to translate innovative science into clinical practice.

The Bio Ascend team has deep oncology and hematology expertise with a proven ability to distill complex scientific ideas into their essential components, as well as extensive experience in planning, executing, and assessing meaningful education for clinicians.

CONNECT

support@bioascend.com

(888) 476-9129

980 North Michigan Avenue, Suite 1400, Chicago, IL 60611